Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

Rhea-AI Summary

Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on organ transplantation and autoimmune diseases, announced that Dr. Steve Perrin will present at NobleCon18 on April 21, 2022 at 11:30 a.m. ET.

The company is advancing its lead compound, tegoprubart, targeting the CD40 Ligand pathway, used for treating transplant patients and autoimmune conditions. A replay of the presentation will be accessible on the Noble Capital Markets’ website and Channelchek.

Argus Session date unavailable

+12.59% session move Open Argus

Details

News Market Reaction – ELDN

The recorded move for ELDN in the trading session of this news was +12.59%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference on Thursday, April 21^st at 11:30 a.m. ET.

A webcast replay of the presentation will be available at Noble Capital Markets’ Conference website at: www.nobleconference.com and on Channelchek at: www.channelchek.com. 

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date of Eledon Pharmaceuticals' presentation at NobleCon18?

Eledon Pharmaceuticals' presentation at NobleCon18 is scheduled for April 21, 2022.

Who is presenting for Eledon Pharmaceuticals at the investor conference?

Dr. Steve Perrin, President and Chief Scientific Officer, will present for Eledon Pharmaceuticals.

What time will Eledon Pharmaceuticals' presentation take place?

The presentation will take place at 11:30 a.m. ET.

Where can I find the webcast replay of Eledon's conference presentation?

The webcast replay will be available on Noble Capital Markets’ Conference website and Channelchek.

What is the main focus of Eledon Pharmaceuticals?

Eledon Pharmaceuticals focuses on developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative diseases.

What is Eledon's lead compound?

Eledon's lead compound is tegoprubart, an anti-CD40L antibody.